Avidian Wealth Enterprises LLC Sells 93 Shares of Danaher Co. (NYSE:DHR)

Avidian Wealth Enterprises LLC lowered its position in shares of Danaher Co. (NYSE:DHR) by 3.4% in the fourth quarter, HoldingsChannel reports. The fund owned 2,619 shares of the conglomerate’s stock after selling 93 shares during the period. Avidian Wealth Enterprises LLC’s holdings in Danaher were worth $601,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Heck Capital Advisors LLC bought a new position in Danaher in the fourth quarter valued at $27,000. Decker Retirement Planning Inc. acquired a new position in shares of Danaher during the 4th quarter worth about $31,000. Golden State Wealth Management LLC bought a new position in shares of Danaher in the 4th quarter valued at about $31,000. Strategic Financial Concepts LLC acquired a new stake in shares of Danaher in the fourth quarter valued at about $31,000. Finally, Pineridge Advisors LLC raised its holdings in Danaher by 63.3% during the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock worth $34,000 after acquiring an additional 57 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 0.3 %

Shares of Danaher stock opened at $202.22 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The firm has a 50-day moving average of $231.17 and a 200-day moving average of $250.62. Danaher Co. has a 52-week low of $196.80 and a 52-week high of $281.70. The stock has a market cap of $146.06 billion, a PE ratio of 38.30, a PEG ratio of 2.68 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the firm posted $2.09 EPS. As a group, sell-side analysts forecast that Danaher Co. will post 7.67 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were paid a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.53%. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on DHR shares. Scotiabank began coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target for the company. Stephens reaffirmed an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. JPMorgan Chase & Co. dropped their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Finally, Guggenheim began coverage on Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price target for the company. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.